모노파 테라퓨틱스(MNPR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $98.31 (-4.27%), 시가총액 $0.37B, 52주 최저~최고 $30.01 ~ $102.05.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to
모노파 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
모노파 테라퓨틱스의 현재 주가는 $98.31 (-4.27%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
모노파 테라퓨틱스의 시가총액은 약 $0.37B입니다.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage,